To assess the release of the proteolytic enzyme cathepsin D in endometriosis, concentrations in peritoneal fluid and serum were measured by ELISA in 54 women with (n ⍧ 33) and without (n ⍧ 21) endometriosis. Surgery was scheduled in either the proliferative or secretory phase of the menstrual cycle. The concentrations of cathepsin D in the peritoneal fluid were markedly elevated in the endometriosis patients (median 58 ng/ml, interquartile range 0-166 ng/ml) as compared to the controls (5 ng/ml, 0-86 ng/ml), especially in women with late stage disease (n ⍧ 19, stages III/IV) and in those not undergoing gonadotrophin-releasing hormone (GnRH) agonist therapy (n ⍧ 15). No significant difference was determined in cathepsin D concentrations of the serum from women with and without endometriosis. We conclude that cathepsin D is an important factor that may contribute to the pathogenesis of endometriosis, possibly by promoting digestion of extracellular matrix proteins. These results have implications for the therapeutic efficacy of GnRH agonists.
Introduction

2000
; Matarese et al., 2000) . Since cathepsin D is induced by growth factors in breast cancer cells (Cavailles et al., 1989) Cathepsin D is an aspartyl acid protease widely distributed in and in the uterus (Maudelonde et al., 1990) , we speculated animal and human cells. It is initially synthesized as an inactive that its concentrations in peritoneal fluid might be similarly 52 kDa precursor (pro-cathepsin D) and proteolytic removal of elevated in women with endometriosis. the aminoterminal pro fragment then results in an enzymatically A previous study showed that in endometriosis patients, active 48 kDa heterodimer consisting of two chains of 14 and endometriotic tissue levels of cathepsin D are significantly 34 kDa (Capony et al., 1987; Fortenberry and Chirgwin, 1995) .
higher than those in eutopic endometrium, suggesting potential Cathepsin D is induced by oestrogens in mammary cancer importance for implantation and invasive growth (Bergqvist cells where its concentration is correlated with a high risk of et al., 1996) . However, to our knowledge, no study of cathepsin metastasis (Spyratos et al., 1989) . Its gene expression is also D levels in peritoneal fluid and serum of endometriosis patients differentially regulated by sex-steroid hormones in human has been published previously. Moreover, the function of uterine (Moulton and Boening, 1983; Maudelonde et al., 1990) cathepsin D under the influence of gonadotrophin-releasing and breast cancer cells (Cavailles et al., 1989; Brouillet hormone (GnRH) analogues has yet to be elucidated, despite et al., 1991) .
the hypo-oestrogenism associated with the GnRH treatment, Endometriosis features progressive growth and invasion and the suggestion (Maudelonde et al., 1990 ) that cathepsin which is oestrogen-dependent (Rock, 1992) . Several lines of D is induced by progesterone in the human endometrium. evidence suggest that cytokines, chemokines, and growth Therefore, the present study was designed to assess the factors are involved in the maintenance and development of menstrual cycle and endometriosis stage variations in proteoendometriotic lesions. Concentrations of several molecules are lytic enzyme cathepsin D levels in peritoneal fluid and serum known to be elevated in the peritoneal fluid of endometriosis from women with this disease. patients, examples being interleukins (IL) and vascular endothelial growth factor (VEGF) (Fakih et al., 1987; McLaren Materials and methods et al., 1996) . Recently, various elevated factors in the peritoneal fluid, for instance insulin-like growth factors (IGF), IGFFifty-four women aged 21-48 years with endometriosis (n ϭ 33) and without endometriosis (n ϭ 21) were enrolled in this study. The study binding proteins and leptin have also been reported (Kim et al., 
Results
Peritoneal fluid
The peritoneal fluid of the women with endometriosis (n ϭ 33) The endometriosis patients were staged from I to IV (n ϭ 19) by the Kruskal-Wallis test (Table I and Figure 1A ). In these patients, elevated cathepsin D levels in the peritoneal group and the control group were matched for age and menstrual fluid were noted in the stages III/ IV group (n ϭ 19) as concentrations of cathepsin D were lower for the GnRH
Since there were insufficient data in normal disease-free women, data agonist-treated patients (n ϭ 15) than for the untreated cases from patients with ovarian cystadenomas were used as the controls. The patients with GnRH agonist pre-treatment had had a 1 or 2 (n ϭ 18) ( Figure 1B , P Ͻ 0.01).
month(s) long wash-out period before operation. All the endometriosis Cathepsin D levels in the serum of the endometriosis patients patients who gave informed consent to GnRH analogue treatment (n ϭ 27; median 0 ng/ml, interquartile range 0-2 ng/ml) were were enrolled in the pre-treatment group; however, some patients not significantly different from those of the control group could not be diagnosed before surgery and some patients did not (n ϭ 20; 0 ng/ml, 0-2 ng/ml) ( Table I) .
accept pre-operative GnRH analogue treatment, being afraid of the side-effects. We therefore had two groups of endometriosis patients with and without GnRH analogue therapy. Basal body temperature
Discussion
of patients was used to determine their cycle phase in this study. The
In the present study, we demonstrated that the concentration numbers of individuals representing proliferative and secretory phases of cathepsin D in peritoneal fluid is significantly elevated in of the menstrual cycle are listed in Table I. untreated women with endometriosis compared to the GnRH
The patients with endometriosis were scored according to the agonist-treated patients or the controls. , 1999) and it is reported that this is also the case for supernatants were then stored at -80°C until assayed. IL-6 (Tseng et al., 1996) . Previously it has been found endometrium (Bergqvist et al., 1996) . Our present findings Thus, the proteolytic enzyme cathepsin D could be involved of the cathepsin D ELISA was Ͻ1 ng/ml, and the standard curve range was 1-100 pg/ml.
in the spreading and development of endometriosis and its endometriosis, indicates that hormonal induction of cathepsin D may not be a major factor. Several lines of evidence suggest that tissue cathepsin D concentrations appear to be correlated more with tumour invasiveness than with hormonal responsiveness, independent of regulation by oestrogen (Spyratos et al., 1989) . Therefore, we suggest that invasion with endometriosis may occur locally with some contribution of cathepsin D regardless of ovarian steroids. However, since peritoneal fluid concentrations of cathepsin D in the GnRH agonisttreated patients were relatively low, it is likely that induction of hypo-oestrogenism may therefore reduce the local invasiveness.
In clinical oncology, serum and tissue levels of cathepsin D have been widely studied with regard to a potential prognostic value, particularly in breast cancer patients (Westley and May, 1996; Pujol et al., 1999) . Overexpression of cathepsin D in tumour tissue was thereby observed to be an independent marker for identifying patients at risk of disease progression. However, elevated cathepsin D serum values have only been recognized in pancreatitis or liver cirrhosis patients, and not in individuals with breast cancer (Brouillet et at., 1991; Leto et al., 1997) . Recent reports have in fact suggested that serum cathepsin D concentrations are not elevated in most cancer patients, regardless of the clinical stage or the tumour size (Leto et al., 1997; Westhoff et al., 1998) . In spite of high cathepsin D levels in endometriotic tissue (Bergqvist et al., 1996) and our present findings for peritoneal fluid, our data also indicate that there is no potential for diagnostic use of serum cathepsin D levels for patients with endometriosis.
In malignant cells, cathepsin D has been found to be overexpressed or abnormally processed, resulting in its cytoplasmic accumulation and excessive secretion (Strojan et al., Strojan et al., 1998) . In endometrial adenocarcinomas, noted in the stages III/IV group as compared to the stages I/II the levels of cathepsin D are higher than in normal endometrium group. (B) No significant variation in cathepsin D levels within the menstrual cycle was noted (P: the proliferative phase; S: the and correlate positively with loss of differentiation and the secretory phase) in any groups marked **. No significant difference degree of myometrial invasion (Nazeer et at., 1992) . Our data was observed between the controls and the GnRH agonist-treated point to elevated cathepsin D levels in the peritoneum due to patients. However, the cathepsin D levels of the untreated patients proteolytic invasion of endometriotic lesions.
(n ϭ 18; n ϭ 10, the proliferative phase; n ϭ 8, the secretory We conclude that cathepsin D is an important factor that phase) were significantly higher than those from patients receiving GnRH agonist treatment (n ϭ 15; n ϭ 9, the proliferative phase; may contribute to the pathogenesis of endometriosis, possibly n ϭ 6, the secretory phase, P Ͻ 0.01).
by digesting extracellular matrix proteins. This information has implications for the therapeutic efficacy of GnRH agonists. measurement in the peritoneal fluid could be a good marker for the severity of the disease.
